MOUNTAIN VIEW, Calif., July 26 /PRNewswire/ -- Aviron (Nasdaq: AVIR)
announced today that Nasdaq has halted trading on Aviron stock, pending news.
Today and tomorrow, the Vaccines and Related Biological Products Advisory
Committee of the U.S. Food and Drug Administration (FDA) is evaluating
FluMist(TM), Aviron's investigational intranasal influenza vaccine.
Nasdaq would resume trading of Aviron stock after the meeting is concluded
and news of the outcome is publicly announced on July 27.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Additional information about the company, including recent press releases,
can be located at http://www.aviron.com .
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
CONTACT:
John Bluth, +1-650-919-3716, or Asha
Jennings, +1-650-919-1429, or investors, Fred Kurland,
+1-650-919-6666, all of Aviron; or media, Ben Butkus of
Fleishman-Hillard, +1-212-453-2000, for Aviron
|
